UCB (OTCMKTS:UCBJF) Reaches New 52-Week High - Here's What Happened

Key Points

• Shares of UCB SA reached a new 52-week high of $239.75 during trading, up from a previous close of $235.70.
• Morgan Stanley upgraded UCB to an "overweight" rating, contributing to a consensus rating of "Buy" among analysts.
• UCB is a biopharmaceutical company focused on developing treatments for neurology and immunology diseases, with key products including Cimzia and Vimpat.

UCB SA (OTCMKTS:UCBJF - Get Free Report) shares hit a new 52-week high on Wednesday . The stock traded as high as $239.75 and last traded at $239.75, with a volume of 13354 shares trading hands. The stock had previously closed at $235.70.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley raised shares of UCB to an "overweight" rating in a research report on Monday, June 23rd. One investment analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, UCB has an average rating of "Buy".

UCB Price Performance

The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78. The firm's 50-day simple moving average is $214.49 and its 200-day simple moving average is $189.49.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.